Alk licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Alk (alkb:dc / omx: alk b) today announced that it has entered into a strategic license agreement with us-based ars pharmaceuticals, inc. (“ars pharma”, nasdaq: spry). the agreement grants alk exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the usa, australia, new zealand, japan and china. the deal delivers on key elements in alk's new strategy allergy+ and supports alk's long-term financial ambitions.
ALK Ratings Summary
ALK Quant Ranking